Journal Article Preprint Epublish
PubMed: 40766148 DOI: 10.1101/2025.07.31.25332518
Genomic and molecular associations with preoperative immune checkpoint inhibition in patients with stage III clear cell renal cell carcinoma.
medRxiv
Authors: Wesley H Chou, Lucy Lawrence, Emma Neham, Shreeram Akilesh, Amy E Moran, Christopher L Corless, Lisa Langmesser, Beyza Cengiz, Kazumi Eckenstein, Jen-Jane Liu, Sudhir Isharwal, Christopher L Amling, Marshall C Strother, Nicholas H Chakiryan, George V Thomas
Affiliations
- Department of Urology, Oregon Health & Science University, Portland, Oregon.
- Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon. Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.
- Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
- Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
- Department of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, Oregon.
- Department of Urology, Portland VA Medical Center, Portland, Oregon.
- Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. Department of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, Oregon.
Abstract
Purpose
Patients with stage III clear cell renal cell carcinoma are at high risk for recurrence after nephrectomy. To mitigate overtreatment, there is a pressing clinical need to determine which patients benefit most from perioperative immune checkpoint inhibition. We performed a multimodal digital spatial analysis of gene and protein expression in stage III primary renal cell carcinomas, a subset of which had preoperative immune checkpoint inhibition exposure.
Materials and Methods
Surgically resected tumors from stage III clear cell renal cell carcinoma patients were analyzed using the Nanostring GeoMx Digital Spatial Profiler. Differential expression analysis was performed and validated using NCT02210117 trial data to identify genes associated with immune checkpoint blockade and clinical response. A gene score was then generated to predict overall survival in patients from The Cancer Genome Atlas.
Results
Among 19 patients, RNA expression significantly differed based on preoperative immune checkpoint blockade and recurrence - CD8+ effector and central-memory T-cell signatures were less prevalent in the treatment-naïve with recurrence group. Three out of four patients with preoperative immune checkpoint inhibition had recurrence. External validation yielded a 4-gene set (GZMK, GZMA, ITGAL, and IL7R); higher gene expression levels predicted better overall survival in The Cancer Genome Atlas cohort (p=0.005).
Discussion
Preoperative immune checkpoint blockade favorably altered the tumor microenvironment to resemble that of treatment-naïve patients without recurrence. However, this did not translate to better clinical outcomes. On external validation, the genes GZMK, GZMA, ITGAL, and IL7R were modifiable with immune checkpoint inhibition and associated with improved survival. Further investigation to assess if patients with low baseline expression of these genes may particularly benefit from perioperative immune checkpoint blockade is warranted.
MeSH
Cells, Genes, Neoplasms, Carcinoma, Renal Cell, Proteomics, Therapeutics, Rna